Terms: = Endocrine gland cancer AND STAG2, RP11-517O1_1, 10735, ENSG00000101972, DKFZp781H1753, SA2, SA-2, FLJ25871, DKFZp686P168, bA517O1_1
95252 results:
1. Diagnostic Efficiency of ACR-TIRADS Score for Differentiating Benign and Malignant Thyroid Nodules of Various Pathological Types.
Xu Y; Pi J; Jinghu Y; Wang X; Xu D; Liu J
Med Sci Monit; 2024 May; 30():e943228. PubMed ID: 38764217
[TBL] [Abstract] [Full Text] [Related]
2. HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway.
Zhou S; Wang Z; Zhao D; Fu Y; Zhang S; Wang Z; Zou X
World J Surg Oncol; 2024 May; 22(1):133. PubMed ID: 38762741
[TBL] [Abstract] [Full Text] [Related]
3. Causal association of sleep traits with the risk of thyroid cancer: A mendelian randomization study.
Zong L; Liu G; He H; Huang D
BMC Cancer; 2024 May; 24(1):605. PubMed ID: 38760772
[TBL] [Abstract] [Full Text] [Related]
4. Weighted metrics are required when evaluating the performance of prediction models in nested case-control studies.
Rentroia-Pacheco B; Bellomo D; Lakeman IMM; Wakkee M; Hollestein LM; van Klaveren D
BMC Med Res Methodol; 2024 May; 24(1):115. PubMed ID: 38760688
[TBL] [Abstract] [Full Text] [Related]
5. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid cancer.
Fu G; Chazen RS; MacMillan C; Witterick IJ
JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
[TBL] [Abstract] [Full Text] [Related]
6. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
7. Dual‑regulated oncolytic adenovirus carrying
Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
[TBL] [Abstract] [Full Text] [Related]
8. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
[TBL] [Abstract] [Full Text] [Related]
9. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract] [Full Text] [Related]
10. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
[TBL] [Abstract] [Full Text] [Related]
11. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
12. CircAGFG1 Promotes Ovarian cancer Progression Through the miR-409-3 p/ZEB1 Axis.
Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
[TBL] [Abstract] [Full Text] [Related]
13. Non-specific uptake of
Li Y; Gao J; Li Y; Duan X; Shen C
Sci Rep; 2024 May; 14(1):11141. PubMed ID: 38750103
[TBL] [Abstract] [Full Text] [Related]
14. Feasibility and complications after transoral endoscopic thyroidectomy via vestibular approach (TOETVA) - a single-center first experience case series.
Kinet S; van Weezelenburg MAS; Pijnenburg A; Stoot JHMB; van Bastelaar J
Langenbecks Arch Surg; 2024 May; 409(1):158. PubMed ID: 38748236
[TBL] [Abstract] [Full Text] [Related]
15. Coexistence of Hashimoto's thyroiditis and papillary thyroid carcinoma revisited in thyroidology, an experience from an endemic region: fad or future?
Cinar I; Sengul I
Rev Assoc Med Bras (1992); 2024; 70(4):e20231380. PubMed ID: 38747877
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
[TBL] [Abstract] [Full Text] [Related]
17. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
[TBL] [Abstract] [Full Text] [Related]
18. FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer.
Kluz-Barłowska M; Kluz T; Paja W; Pancerz K; Łączyńska-Madera M; Miziak P; Cebulski J; Depciuch J
Sci Rep; 2024 May; 14(1):11025. PubMed ID: 38744861
[TBL] [Abstract] [Full Text] [Related]
19. IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3/HIF-1α pathway.
Guo QY; Song JN; Chen YM; Yuan HN; Xue WS; Sun Y; Niu XL; Wang Y; Chen X
Med Oncol; 2024 May; 41(6):155. PubMed ID: 38744773
[TBL] [Abstract] [Full Text] [Related]
20. Impact on Long-term Survival of a Standardized Histopathological Protocol on the R1 Incidence in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma.
Moiş E; Graur F; Puia C; Vlad I; Moldovan S; Ursu CP; Nechita VI; Vălean D; Furcea L; Puia A; Zaharie F; Popa C; Bodea R; Iancu C; Rusu I; Hajjar NA
Chirurgia (Bucur); 2024 Apr; 119(2):171-183. PubMed ID: 38743830
[No Abstract] [Full Text] [Related]
[Next]
